Literature DB >> 3918367

Influence of in vivo immunosuppressive drugs on production of lymphokines.

E Dupont, K Huygen, L Schandené, M Vandercruys, K Palfliet, J Wybran.   

Abstract

The influence in vivo of immunosuppressive drugs (cyclosporine, azathioprine, and corticosteroids) on the production of various lymphokines (alpha and gamma interferon, interleukin 2), both in organ transplant recipients and in normal volunteers taking 100 mg hydrocortisone orally has been studied. To avoid interference with the rejection process or viral infection, patients were studied in a steady state with low maintenance immunosuppression consisting of prednisolone combined with azathioprine or with cyclosporine. In patients treated with both drug regimens, significant depression of production of the three lymphokines was found. Normal volunteers challenged with 100 mg hydrocortisone showed inhibition of production of interleukin 2 and alpha and gamma interferon in 4 hr, a time corresponding to the nadir of T cell lymphopenia, affecting the OKT4 subset preferentially. The percentage of OKT8 cells remained unchanged. Percentages of large granular lymphocytes increased, but their absolute number was not significantly modified. Changes in lymphocyte markers were fully reversible after 24 hr, but interleukin 2 production remained markedly depressed, showing that the redistribution patterns induced by corticosteroids on lymphocyte subsets may be dissociated from functional consequences.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3918367     DOI: 10.1097/00007890-198502000-00007

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  9 in total

1.  Self perceived work related stress and the relation with salivary IgA and lysozyme among emergency department nurses.

Authors:  Y Yang; D Koh; V Ng; C Y Lee; G Chan; F Dong; S H Goh; V Anantharaman; S E Chia
Journal:  Occup Environ Med       Date:  2002-12       Impact factor: 4.402

Review 2.  Pharmacodynamic monitoring of cyclosporin.

Authors:  W M Awni
Journal:  Clin Pharmacokinet       Date:  1992-12       Impact factor: 6.447

3.  Salivary lysozyme: a noninvasive marker for the study of the effects of stress of natural immunity.

Authors:  S Perera; M Uddin; J A Hayes
Journal:  Int J Behav Med       Date:  1997

4.  The type I interferon signaling pathway is a target for glucocorticoid inhibition.

Authors:  Jamie R Flammer; Jana Dobrovolna; Megan A Kennedy; Yurii Chinenov; Christopher K Glass; Lionel B Ivashkiv; Inez Rogatsky
Journal:  Mol Cell Biol       Date:  2010-08-02       Impact factor: 4.272

5.  Combination therapy of cyclosporine with steroid inhibits gamma-interferon and interleukin-1 gene expression at the level of mRNA synthesis in vivo.

Authors:  N Yoshimura; T Oka; M Kita; H Teraoka; Y Hirai
Journal:  J Clin Immunol       Date:  1989-07       Impact factor: 8.317

Review 6.  Methods for clinical monitoring of cyclosporin in transplant patients.

Authors:  R J Dumont; M H Ensom
Journal:  Clin Pharmacokinet       Date:  2000-05       Impact factor: 6.447

7.  Cellular immunosuppression in children with acute lymphoblastic leukemia: effect of consolidation chemotherapy.

Authors:  Y Komada; S L Zhang; Y W Zhou; M Hanada; T Shibata; E Azuma; M Sakurai
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

8.  Hormonal and immunological pattern in a patient with acquired immunodeficiency syndrome related complex and Cushing's syndrome.

Authors:  R Rossi; A P Tommaselli; N Panza; M R Ghiggi; G Rezza; M Giuliani; B Suligoi; R De Mercato; G Lombardi
Journal:  J Endocrinol Invest       Date:  1992-12       Impact factor: 4.256

9.  Glucocorticoid receptor dimers control intestinal STAT1 and TNF-induced inflammation in mice.

Authors:  Marlies Ballegeer; Kelly Van Looveren; Steven Timmermans; Melanie Eggermont; Sofie Vandevyver; Fabien Thery; Karen Dendoncker; Jolien Souffriau; Jolien Vandewalle; Lise Van Wyngene; Riet De Rycke; Nozomi Takahashi; Peter Vandenabeele; Jan Tuckermann; Holger M Reichardt; Francis Impens; Rudi Beyaert; Karolien De Bosscher; Roosmarijn E Vandenbroucke; Claude Libert
Journal:  J Clin Invest       Date:  2018-06-25       Impact factor: 14.808

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.